Multiple Myeloma
Multiple Myeloma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
43
Clinical Trials
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BIOLOGICAL-SPECIMEN
Collection of Biological Specimens from Volunteers or Patients with Multiple Myeloma and other Plasma Cell Dyscrasias
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BTKI/IIT
Use of Bruton tyrosine kinase inhibitors (BTKI) in patients with Waldenstrom macroglobulinemia (WM) with neuropathy and Bing-Neel syndrome, and non-IgM lymphoplasmacytic lymphoma
Learn More
Multiple Myeloma
Phase I/II
Enrolling
nct/study# NCT05372354 / CA057-003
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I/II
Enrolling
nct/study# NCT06988488 / CA057-1040
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT06121843 / CA088-1005
A Phase 1, Open-Label Study that will test BMS-986393 in combination with 3 dual agent combinations of BMS-986393 (a chimeric antigen receptor CAR T-cell) with investigational treatments {Alnuctamab, Mezigdomide or Iberdomide} for safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics.
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / CAR-T-CELL-RRMM
CAR-T Cell Therapy Outcomes in Relapsed/Refractory Multiple Myeloma: A Retrospective Analysis Myeloma: A Retrospective Analysis
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.